Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P0DPH7

UPID:
TBA3C_HUMAN

ALTERNATIVE NAMES:
Alpha-tubulin 2; Alpha-tubulin 3C; Tubulin alpha-2 chain

ALTERNATIVE UPACC:
P0DPH7; A6NJQ0; Q13748; Q5W099; Q6PEY3; Q96F18

BACKGROUND:
The Tubulin alpha-3C chain, identified by alternative names such as Alpha-tubulin 2 and Tubulin alpha-2 chain, is integral to the formation and function of microtubules. These structures are vital for maintaining cell shape, enabling movement, and facilitating the segregation of chromosomes during cell division. The protein's ability to bind GTP and GDP is essential for microtubule stability and dynamics.

THERAPEUTIC SIGNIFICANCE:
Exploring the Tubulin alpha-3C chain's function offers a pathway to novel therapeutic approaches. Given its critical role in microtubule assembly and cell cycle progression, targeting this protein could lead to breakthroughs in treatments for diseases characterized by abnormal cell growth, such as cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.